About cephalosporins Cephalosporins are bactericidal antibiotics and act by inhibiting cell wall synthesis. They inhibit a wide variety of gram-positive and gram-negative bacteria. They are considered broad-spectrum antibiotics with similar activities to those of ampicillin. They are sometimes grouped into "generations" by their antimicrobial properties. Cephalosporin drugs can be grouped into five classes or generations. The gram-negative antimicrobial property significantly increases with each newer generation of cephalosporin.
Technavio's analysts forecast the global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019.
Covered in this report In this report, Technavio covers the present scenario and growth prospects of the global cephalosporin drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria.
Technavio's report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
- Abbott - Aspen Pharmacare - AstraZeneca - Aurobindo Pharma - Basilea Pharmaceuticals - Baxter - Biocon - Corden Pharma - Cornerstone Therapeutics - Eli Lilly - F. Hoffmann-La Roche - Flynn Pharma - Hospira - Incepta Pharmaceuticals - Johnson & Johnson - Kyorin Pharmaceutical - Lupin Pharmaceuticals - Orchid Pharma - Par Pharmaceutical - Pernix Therapeutics - Sanofi - Shionogi - Sun Pharmaceutical - Takeda Pharma - Theravance Biopharma - Wockhardt Market driver - Special regulatory designation for pipeline molecules - For a full, detailed list, view our report Market challenge - Development of drug resistance - For a full, detailed list, view our report Market trend - Use of combination therapies - For a full, detailed list, view our report
Key Questions Answered in this Report - What will the market size be in 2019 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors?
Our reports have been used by over 10K customers, including:
The global cancer cachexia market was valued at USD 2,256.35 million in 2020, and it is expected to reach USD 2,974.49 million by 2026, registering a CAGR of 4.47% during the forecast period. The outbreak of COVID-19 impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing...
The peptide therapeutics market was valued at US$ 24,878.55 million in 2019 and is projected to reach US$ 50,003.15 million by 2027; it is expected to grow at a CAGR of 9.2% during 2020–2027. The growth of the peptide therapeutics market is mainly attributed to the growing investments on peptide therapeutics and increasing prevalence of metabolic...
The Veterinary Pain management market was valued at USD 1,197 million in 2020, and it is expected to reach USD 1,910 million in 2026, registering a CAGR of nearly 6.30% during the forecast period. The global outbreak of COVID-19 has impacted all industries including veterinary pain medicine. Pet parents are advised to keep a safe distance...
Amyloidosis (Metabolic Disorder) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Drugs in Development, 2021, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape. Abnormal accumulation of amyloid...
The Multiple Sclerosis Therapeutics market was valued at US$ 24,026.90 million in 2019 and it is projected to reach US$ 39,223.59 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027. The growth of the multiple sclerosis therapeutics market is mainly attributed to factors, such as growing prevalence of multiple...
“Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complicated skin and soft tissue infections (cSSTI) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.
The global IV and oral iron drugs market is expected to grow due to the prevalence...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.